Stakeholder Insight: Prostate Cancer

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-10-11

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The prostate cancer market is reaching maturity, and major players’ sales have been eroded by the launch of various LHRH agonist depot formulations. Safety concerns with AstraZeneca’s Casodex (bicalutamide) have also seen a significant proportion of physicians switching to alternatives. Establishing the optimal timing of antihormonal therapy will provide the key to market growth.


Scope

  • Current treatment practices for hormone-sensitive and hormone-refractory prostate cancer based on 180 physician interviews in the seven major markets
  • Changes in prescribing habits for prostate cancer between 2003 and 2005
  • Physician awareness and ratings of late-stage pipeline drugs for prostate cancer, including Abbott’s Xinlay and Dendreon’s Provenge
  • Potential drug regimens for prostate cancer in 2010 based on physicians’ opinion


    • Report Highlights
    The use of bicalutamide has significantly decreased in localized stage between 2003 and 2005 since the EPC trial demonstrated increased mortality with bicalutamide 150mg. This has not only undermined physicians’ confidence in the drug in localized stage but it has also affected the uptake of the drug in locally advanced and advanced stage disease.

    TAB has failed to conclusively establish survival benefit in clinical trials and remains used in a minority of patients in advanced stage. Cost is also a problem for TAB, even in the US. However, oral drugs are expected to be reimbursable under Medicare from 2006 and that should increase the uptake of anti-androgens as well as that of TAB regimens.

    Although physicians are hopeful of molecular-targeted agents for HRPC, primary research suggests that its use will remain relatively low in 2010 and they are not expected to be used in a level similar to that seen in other tumors. However, opinion leaders have identified angiogenesis inhibitors to be the most promising for prostate cancer.


    Reasons to Purchase

  • Quantify the size and scope of the antihormonals market for prostate cancer by examining the uptake of LHRH agonists and anti-androgens
  • Examine the potential of late-stage pipeline drugs for prostate cancer through physician awareness and ratings.
  • Develop commercial strategies by analyzing physicians’ opinion on the potential drug regimens for prostate cancer in 2010

    • Table of Contents

    Other users found this report page using the following search terms: Prostate Cancer prostate cancer patients remission monotherapy dr estramustine decrease percent prescribing

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.